L. Estradarodgers et al., SUBSTRATE SELECTIVITY OF MOUSE N-ACETYLTRANSFERASE-1, N-ACETYLTRANSFERASE-2, AND N-ACETYLTRANSFERASE-3 EXPRESSED IN COS-1 CELLS, Drug metabolism and disposition, 26(5), 1998, pp. 502-505
Two human acetyl-CoA:arylamine N-acetyltransferases (NAT1 and NAT2) ha
ve been identified. Therapeutic and carcinogenic agents that are subst
rates for these isoenzymes (including isoniazid, sulfamethazine, p-ami
nobenzoic acid, 5-aminosalicyclic acid, and P-aminofluorene) have been
used to evaluate the role of the N-acetylation polymorphisms of NAT1
and NAT2 in the treatment of disease and differential risk of various
cancers among individuals of differing acetylator phenotypes. The mous
e is frequently used as a model of the human acetylator polymorphism.
As three Nat isoenzymes have been identified in mouse, it is necessary
to determine the selectivity of mouse Nats toward common NAT substrat
es. In the present study, Nat1, Nat2*8, and Nat3* were expressed in C
OS-l cells, and their substrate selectivity was evaluated with various
substrates. Under the conditions used, mouse Nat2 had 20-, 2.4-, and
5.4-fold higher catalytic activity for p-aminobenzoic acid, 5-aminosal
icylic acid, and 5-aminofluorene, respectively, than Natl. Isoniazid N
-acetylation was catalyzed only by mouse Natl. For the substrates test
ed in this study, mouse Nat3 exhibited activity only toward 5-aminosal
icylic acid and only at 1/20 the activity shown by Nat2. In addition,
p-aminobenzoylglutamate, the first endogenous NAT substrate identified
, was selective for mouse Nat2, These results further support the func
tional analogy of mouse Nat2 and human NAT1.